

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this supplemental notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this supplemental notice.



Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

SUPPLEMENTAL NOTICE OF 2023 ANNUAL GENERAL MEETING

Reference is made to the notice of the annual general meeting (the “**Original Notice**”) of Qyuns Therapeutics Co., Ltd. (the “**Company**”) dated April 29, 2024 which sets out the resolutions to be considered by shareholders of the Company (“**Shareholders**”) at the annual general meeting to be held at North Conference Room, 2nd Floor, Building 1, No.907 Yaocheng Avenue, Taizhou City, Jiangsu Province, the PRC on Friday, May 31, 2024 at 2:00 p.m. (the “**AGM**”).

Hangzhou Quanyi Investment Management Partnership (General Partnership) (杭州荃毅投資管理合夥企業(普通合夥)), the controlling Shareholder of the Company, has submitted an extraordinary proposal to the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company. In accordance with the relevant laws and regulations and the Company’s articles of association, the Board hereby presents such extraordinary proposal at the AGM for consideration and approval by Shareholders.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the AGM, which will be held as originally scheduled, will consider and, if thought fit, pass the following ordinary resolution, in addition to the resolutions set out in the Original Notice:

ORDINARY RESOLUTION

9. To consider and approve the provision of a guarantee by the Company to its subsidiary for a guarantee line of not more than RMB100 million in aggregate.

For details of the ordinary resolution, please refer to the Appendix to this supplemental notice.

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan

Chairman of the Board and Executive Director

Hong Kong, May 14, 2024

As at the date of this supplemental notice, the board of directors of the Company comprises Mr. Qiu Jiwan as chairman and executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi, Mr. Wu Zhiqiang and Dr. Xue Mingyu as non-executive directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive directors.

Notes:

- (1) A revised form of proxy is enclosed with this supplemental notice. Whether or not you are able to attend the AGM, you are requested to complete the accompanying revised form of proxy in accordance with the instructions printed thereon and return the same to the Company's H share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong as soon as practicable and in any event not less than 24 hours before the time specified for the holding of the AGM or any adjournment thereof (as the case may be). Completion and return of the revised form of proxy will not preclude you from attending and voting in person at the AGM or any adjournment thereof.
- (2) Please refer to the Original Notice for details in respect of the other resolutions to be proposed at the AGM, eligibility for attending the AGM, appointment of proxy, registration procedures, closure of register of members and other relevant matters.

APPENDIX:

Jiangsu Cellularforce Biopharma Co., Ltd. (江蘇賽孚士生物技術有限公司) (“**Cellularforce**”), a subsidiary of our Company, plans to apply for a credit line from commercial banks and other financial institutions for its daily operation needs. The Company plans to provide a guarantee line for Cellularforce of not more than RMB100 million in aggregate. The validity period of this guarantee line shall be effective from the date of consideration and approval by Shareholders at the AGM until the date of the annual general meeting for the year of 2026 when the line shall expire and be reconsidered. The said guarantee line may be utilized on a revolving basis within the validity period and the balance of the guarantee at any one point in time during the guarantee period shall not exceed the amount of the guarantee line as considered and approved by the Shareholders at the annual general meeting.

The Board proposes that the Shareholders authorize the Board at the AGM and then to the Board to delegate to Mr. Qiu Jiwan, the chairman of the Company, or the authorized agent designated by him to negotiate with relevant financial institutions with cooperation, and authorize Mr. Qiu Jiwan to sign all contracts, agreements, certificates and other legal documents related to the guarantee on behalf of the Board.